GLP-1 for Obesity in Older Adults: AGS Framework and USMLE

The American Geriatrics Society (AGS) has released a framework to help clinicians prescribe obesity medications safely in older adults, including GLP-1 medications that act through gut-derived hormonal pathways. It is organized around a series of cases and applies the Geriatrics 5Ms to incretin therapy. This is practice guidance from a society working group, not the result of a new clinical trial.

What happened

The paper comes from the AGS Healthy Aging Special Interest Group and appeared in the Journal of the American Geriatrics Society. The lead author is Elias M. Wisdom, and the title is "Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing" (2026).

The framework starts from a known gap. These drugs offer promising benefits for weight management, glycemic control, and other health conditions, but older adults are underrepresented in clinical trials. So the authors lean on geriatric principles rather than on trial data in older patients.

The paper applies the Geriatrics 5Ms (Mind, Mobility, Medications, Multicomplexity, and Matters Most) to incretin therapy. According to the announcement, the authors emphasize several points:

• Clinicians should weigh age-related factors such as sarcopenia and frailty, the risk of lean muscle loss, malnutrition, and dehydration.
• Safe prescribing requires a pretreatment assessment of functional status, nutritional adequacy, and cognitive impairment.
• Treatment should be paired with co-interventions such as resistance training and adequate dietary protein intake.
• For some older adults, a team-based approach may be most appropriate. It could include a registered dietitian, a physical therapist, a fitness trainer, and a behavioral health professional.

The announcement does not describe specific drug-by-drug recommendations, dosing, or thresholds, so this article does not either.

Why it matters

Obesity in older adults is not simply a younger patient's problem at a later age. Aging changes body composition: lean mass declines and fat tends to make up a larger share of weight. A person can have excess adiposity and still have low muscle mass and strength, a picture often called sarcopenic obesity. Weight loss in that setting can come partly from lean tissue, which is why the framework stresses muscle loss, resistance training, and protein intake.

The risks the AGS highlights are also physiologically predictable. GLP-1-based drugs reduce appetite and slow gastric emptying. In a frail patient with marginal nutrition, that can mean inadequate calorie and protein intake. Nausea, vomiting, or diarrhea can cause volume depletion, and in an older adult with reduced renal reserve that can lead to prerenal azotemia, orthostatic hypotension, and falls.

The framework also reflects a broader shift in geriatrics. Instead of asking "does this drug lower weight?", the 5Ms ask what matters most to the patient, how the drug affects mobility and cognition, and how it fits with the rest of the medication list. That approach appears throughout Step 2 CK geriatrics questions.

What to know for the USMLE — high-yield pharmacology and geriatrics

• Incretin effect: Oral glucose produces a larger insulin response than IV glucose because gut hormones amplify insulin release. GLP-1 is made by intestinal L cells (ileum and colon), derived from proglucagon. GIP comes from K cells in the duodenum and jejunum.
• GLP-1 actions: It increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety through central appetite pathways. Because insulin release depends on glucose, hypoglycemia is uncommon unless the drug is combined with insulin or a sulfonylurea.
• Drug classes: GLP-1 receptor agonists (exenatide, liraglutide, semaglutide, dulaglutide) are injectable peptides resistant to degradation. DPP-4 inhibitors (sitagliptin, linagliptin) block breakdown of endogenous incretins and have little effect on weight. Tirzepatide is a dual GIP/GLP-1 receptor agonist. The AGS announcement does not say which specific drugs the framework covers, so treat these as class knowledge.
• Adverse effects: Nausea, vomiting, diarrhea, and constipation are the most common. Know the associations with acute pancreatitis, cholelithiasis/cholecystitis, and delayed gastric emptying.
• Contraindications: A personal or family history of medullary thyroid carcinoma and MEN2 are classic exam contraindications for GLP-1 receptor agonists. This stems from thyroid C-cell tumors seen in rodent studies.
• Dehydration and kidneys: GI losses plus reduced intake can precipitate prerenal AKI. Aging lowers GFR, so renal reserve is smaller even when serum creatinine looks normal.
• Sarcopenia and frailty: Sarcopenia is age-related loss of muscle mass and strength. Frailty is a state of reduced physiologic reserve and vulnerability to stressors. Resistance exercise and adequate protein are the standard supports for muscle.
• Geriatric pharmacokinetics: Aging brings reduced renal clearance, a lower proportion of lean mass, and a larger volume of distribution for lipophilic drugs. Polypharmacy raises the risk of interactions and of a prescribing cascade, where a side effect is treated as a new problem with another drug.
• Geriatrics 5Ms: Mind (cognition, mood), Mobility (function, falls), Medications (appropriateness, deprescribing), Multicomplexity (multiple conditions, social context), Matters Most (the patient's goals). Expect this as a framework for choosing the next best step.
• Comprehensive geriatric assessment: Assessing function (ADLs/IADLs), nutrition, and cognition before starting a high-impact therapy is consistent with standard geriatric practice.

Limitations

This is not new research, and it should not be read as evidence that these drugs are safe or effective in older adults. The announcement describes a practical approach built around cases, and it states that older adults remain underrepresented in clinical trials. Case-based guidance tells clinicians how to think, but it cannot supply outcome data in the groups that trials left out.

The details of the framework are also not available in the announcement. We do not know how it handles specific drugs, dosing, monitoring schedules, or when to stop treatment. The summary reflects a news report and a short abstract-level description, not a full reading of the paper. Anyone who needs the specifics should read the original article in the Journal of the American Geriatrics Society (DOI: 10.1111/jgs.70769).

Finally, this article is educational. It is not advice for any individual patient, and treatment decisions belong to a patient and their clinician.

FAQ

What is the AGS framework for obesity medications in older adults?

It is a practical, case-based approach from the AGS Healthy Aging Special Interest Group. It applies the Geriatrics 5Ms to prescribing obesity medications, including GLP-1 drugs, in older patients.

Why are older adults a special concern with GLP-1 medications?

Older adults are underrepresented in clinical trials. They are also more likely to have sarcopenia, frailty, malnutrition, and vulnerability to dehydration. The AGS framework emphasizes these risks, along with the risk of lean muscle loss.

What does the framework recommend alongside medication?

According to the announcement, it recommends pairing treatment with resistance training and adequate dietary protein. For some patients it suggests a team that may include a dietitian, physical therapist, fitness trainer, and behavioral health professional.

Key takeaways

• The AGS released a case-based framework that applies the Geriatrics 5Ms to obesity medications, including GLP-1 drugs, in older adults. It is guidance, not a new trial.
• The focus is on assessing function, nutrition, and cognition first, and on risks such as sarcopenia, frailty, muscle loss, malnutrition, and dehydration, with resistance training and adequate protein as co-interventions.
• For the USMLE, connect the incretin mechanism (GLP-1 from L cells, DPP-4 degradation, delayed gastric emptying, adverse effects, MTC/MEN2 contraindication) with geriatric pharmacology (reduced renal reserve, polypharmacy, prescribing cascades).